- •Corneal Disease
- •Preface
- •Contents
- •Contributors
- •Core Messages
- •Organisms
- •Detection
- •Acid Fast Smears
- •Culture Media
- •Molecular Tests
- •Nucleic Acid Hybridization Probes
- •Line Probes
- •DNA Sequencing
- •FISH (Fluorescent In Situ Hybridization) Assay
- •DNA Microarray
- •Pulse Field Gel Electrophoresis (PFGE)
- •Management
- •Clinical Diagnosis
- •Medical Therapy
- •Surgical Intervention
- •Penetrating Keratoplasty
- •Corneal Cross-Linking
- •Summary for the Clinician
- •References
- •Core Messages
- •Introduction
- •Epidemiology
- •Visual Morbidity
- •Documentation
- •Causative Factors
- •Causative Bacteria
- •Investigation of Keratitis
- •Laboratory Diagnosis: Susceptibility Testing
- •Susceptibility and Resistance of Bacterial Isolates
- •Treatment: Antimicrobials
- •Current Antimicrobials in Use
- •The Fluoroquinolones
- •Aminoglycosides
- •Cephalosporins
- •Other Antimicrobials Used
- •Development of Existing and New Classes of Drugs
- •Tigecycline
- •Linezolid
- •Meropenem
- •Combination Therapy
- •Drug Delivery to the Cornea
- •Novel Methods of Drug Delivery to the Cornea
- •Conclusion
- •References
- •3: Heredity of Keratoconus
- •Introduction
- •Is Keratoconus a Heritable or Genetic Disease?
- •Mutational Screening of Candidate Genes in Keratoconus
- •Visual System Homeobox Gene 1 (VSX1)
- •Superoxide Dismutase 1 (SOD1)
- •Interleukin 1 (IL1) Superfamily
- •Collagen Genes
- •Genetic Mapping in Keratoconus
- •Genetics of Keratoconus – Mendelian or Complex?
- •References
- •4: Advance in Corneal Imaging
- •Introduction
- •In Vivo Confocal Microscopy (IVCM)
- •Principles of Confocal Microscopy
- •The Normal Cornea
- •Clinical Applications
- •Infectious Keratitis
- •Corneal Dystrophies
- •Refractive Surgery
- •Corneal Surgery
- •Other Clinical Applications
- •Limitations of IVCM
- •Anterior Segment Ocular Coherence Tomography (OCT)
- •Clinical Applications
- •Corneal Thickness Assessment
- •Refractive Surgery
- •Corneal Grafts
- •Limitations
- •Conclusion
- •References
- •Core Messages
- •Introduction
- •“Angiogenic Privilege of the Cornea” or “How Does the Normal Corneal Maintain Its Avascularity?”
- •General Mechanisms
- •Corneal Hemangiogenesis After Low-Risk Keratoplasty
- •Corneal Hemangiogenesis After High-Risk Keratoplasty
- •Corneal Lymphangiogenesis: Essential for Corneal Graft Rejection
- •Corneal Lymphangiogenesis in Dry Eye
- •Imaging of Corneal Lymphatic Vessels
- •Novel Anti(lymph)Angiogenic Treatment Options at the Cornea
- •Current Treatment Options for Immature Corneal (Blood and Lymphatic) Vessels
- •Steroids
- •Anti-VEGFs (Bevazicumab, Ranibuzumab, Pegaptanib, VEGF Trap)
- •Anti-IRS 1-Strategies (Antisense Oligonucleotides Against IRS 1)
- •Treatment Options for Mature Corneal Vessels
- •Unmet Needs and Future Directions
- •References
- •Core Messages
- •Introduction
- •Retrieval of Donor Tissue
- •Technical Aspects
- •Microbiological Aspects
- •Tissue Evaluation Aspects
- •Corneal Storage
- •Moist Chamber Storage of the Donor Eye
- •Technical Aspects
- •Storage Period
- •Microbiological Safety
- •Tissue Evaluation
- •Hypothermic Storage of the Corneoscleral Button
- •Technical Aspects
- •Storage Period
- •Microbiological Safety
- •Tissue Evaluation
- •Organ Culture (Normothermic Storage) of the Corneoscleral Button
- •Technical Aspects
- •Storage Period
- •Microbiological Safety
- •Tissue Evaluation
- •Other Aspects
- •Pre-cutting of Corneal Tissue for Endothelial Keratoplasty (EK)
- •Microkeratome Cutting
- •Femtosecond Laser Cutting
- •Stripping of Descemet’s Membrane with Endothelium
- •Donor Considerations for EK
- •References
- •7: Infant Keratoplasty
- •Core Messages
- •Introduction
- •Indications for Surgery
- •Visual Outcome
- •Patient Selection
- •Patient Assessment
- •Ancillary Testing
- •Donor Tissue
- •Intraoperative Considerations
- •Concurrent Surgical Procedures
- •Postoperative Considerations
- •Suture Management
- •Optical Correction and Amblyopia Therapy
- •Postoperative Complications
- •Glaucoma
- •Graft Rejection
- •Graft Failure
- •Alternatives to Penetrating Keratoplasty
- •Conclusion
- •References
- •Index
Index
A
ABO-matched corneas, 101
Acanthamoeba, 56 Amblyopia therapy, 115 Aminoglycosides, 10, 28 Amiodarone, 61 Amniotic membrane, 67 Angiogenic privilege, 73 Aniridia, 71
Anterior synechia, 112 Anterior vitrectomy, 114
Antisense oligonucleotides, 85–86 Anti-VEGFs, 72, 82–85
Aspergillus fungi, 56
Atopic keratoconjunctivitis, 61 Avascular tissues, 74
Avellino macular central dystrophy, 58
B
Besifloxacin, 29–30, 33
Bevazicumab, 82–85
Bowman’s layer dystrophies, 58
Bowman’s membrane, 55
Brittle cornea syndrome, 49
C
Carbol fuschin-based stains (Kinyoun (cold)), 5–6
Central cloudy dystrophy of François, 58 Central mosaic, 58
Cephalosporins, 29
CHED. See Congenital hereditary endothelial dystrophy (CHED)
Chemical burns, 71, 76 Chloroquine, 61 Ciproflloxacin, 25, 26
Collaborative corneal transplantation study, 75
Collagen cross-linking, 37 Collagen genes, 43–44 Confocal microscopy, 78
Congenital corneal opacities, 109 Congenital glaucoma, 108
Congenital hereditary endothelial dystrophy (CHED), 108
Congenital hereditary stromal dystrophy, 108 Contact lens-induced corneal changes, 61 Contact lens wear, 22, 71
Corneal angiogenesis, 71
Corneal angiogenic privilege, 71, 74 Corneal cross-linking, 14
Corneal dystrophies, 57–59 Corneal endothelium, 93 Corneal epithelium, 55 Corneal graft rejection, 77–80 Corneal grafts, 66–68 Corneal preservation, 91 Corneal refractive surgery, 65 Corneal rings, 66
Corneal rupture, 49 Corneal surgery, 56, 61 Corneal wound healing, 56
Corneoscleral button, 93, 97–101 Corticosteroids, 13 Cyclosporine, 82
Cylokernlin, 37
D
DALK. See Deep anterior lamellar keraloplasty (DALK)
Debridement, 13
Deep anterior lamellar keraloplasty (DALK), 66, 77, 118
Deep lamellar keratoplasty, 61 Dermoid, 108
Descemet membrane, 55, 56
T. Reinhard, F. Larkin (eds.), Corneal Disease, |
123 |
DOI 10.1007/978-3-642-28747-3, © Springer-Verlag Berlin Heidelberg 2013 |
|
124 |
Index |
|
|
Descemet’s membrane automated endothelial keratoplasty (DMAEK), 103
Descemet’s membrane endothelial keratoplasty (DMEK), 101, 103
Descemet stripping automated endothelial keratoplasty (DSAEK), 101, 102
Descemet stripping endothelial keratoplasty (DSEK), 2, 61, 101, 118
DMAEK. See Descemet’s membrane automated endothelial keratoplasty (DMAEK)
DMEK. See Descemet’s membrane endothelial keratoplasty (DMEK)
DNA microarray, 9 DNA sequencing, 9 Donor eye, 96–97 Donor tissue, 93 Dry eye, 61, 80
DSAEK. See Descemet stripping automated endothelial keratoplasty (DSAEK)
DSEK. See Descemet stripping endothelial keratoplasty (DSEK)
E
EBAA. See Eye Bank Association of America (EBAA)
EBMD. See Epithelial basement membrane (EBMD)
Endophthalmitis, 94 Endothelial cell counts, 112 Endothelial graft, 66 Enucleation, 95
Epithelial basement membrane (EBMD), 58 European Eye Bank Association (EEBA), 92 Exposure keratopathy, 108
Eye bank, 92
Eye Bank Association of America (EBAA), 92
F
Fabry’s disease, 61
Femtosecond laser-assisted flaps, 65 Femtosecond laser cutting, 102–103 FISH. See Fluorescent in situ hybridization
(FISH) Flieringa ring, 113
Fluorescent in situ hybridization (FISH), 9 Fluorescent stains, 6
Fluoroquinolones, 10, 28, 29 Fuch’s endothelial dystrophy, 49, 59
Fusarium, 56
G
Genetic mapping, 44–47
Glaucoma, 108, 116
Glycopeptides, 29
Graft failure, 108, 117
Graft rejection, 116–117
Granular, 58
GS101, 82
H
Hemangiogenesis, 75 Herpes infection, 100 Herpes simplex keratitis, 21 Herpetic keratitis, 74
High-risk keratoplasty, 71, 72, 77 HLA-matched cornea, 101 Hypothermic storage, 97–98 Hypoxia (contact lens), 76
I
Immune reflex arc, 73 Immune rejection(s), 77, 108 Infant keratoplasty, 107 Infection, 1
Infectious keratitis, 56–57 Interface, 61
Interleukin 1, 43 Intracorneal rings, 65 Intraocular pressure, 110
Intraoperative lens extrusion, 113
In vivo confocal microscopy (IVCM), 53–54, 81
In vivo multiphoton imaging, 81 IVCM. See In vivo confocal microscopy
(IVCM)
K
Keratitis, 71, 76, 108
Keratoconus, 37, 49, 61, 66, 108
Keratocyte, 56
Keratoglobus, 49
L
Lamellar endothelial keratoplasty, 92 LASEK, 2
Laser in situ keratomileusis, 65 LASIK, 2, 59, 65
Lensectomy, 114
Index |
125 |
|
|
Lifting of the flap, 14 Light microscopy, 100 Linezolid, 30, 33 Linkage studies, 46 Liposomes, 10 Lowenstein-Jensen agar, 7
Low-risk keratoplasty, 72, 76 Lymphangiogenesis, 75 Lymphangiogenic privilege, 72 Lymphatic vessels, 71, 79, 81
M
Macrolides, 10 Marfan syndrome, 61
Mc Carey and Kaufman, 95 Media(solid) Chocolate Agar Sheep
Blood Agar Lowenstein Jensen Media, 5
Meesmanndystrophy, 37, 58 Mendelian disorders, 47 Meropenem, 30–31, 33 Metabolic disorders, 108 Microbiological safety, 97–100 Microsatellite markers, 45 Moist chamber storage, 96–97 Molecular tests, 8
Mutational screening, 38–42
Mycobacteria chelonae complex, 4 Mycobacterial keratitis, 1
Mycobacterium M. abscessus, 4 M.asiaticum, 2
M.avium complex, 2 M.chelonae, 3
M. chelonae, 4 M.flavescens, 2 M.fortuitum, 3 M. fortuitum, 4 M.gordonae, 2
M.immnogenum, 3
M.immunogenum, 3 M. immunogenum, 4 M. leprae, 4 M.marinum, 2
M.nonchromogenicum, 2 M.skulgai, 4 M.smegmatis, 3 M.szulgai, 2
M.terrae, 2, 4
M.triviale, 2
M. tuberculosis, 4, 6
N
Nanoparticles, 13 Nephropathic cystinosis, 61
Neurotrophic keratopathy, 21, 87 Nucleic acid hybridization probes, 8
O
OCT. See Optical coherence tomography (OCT) Ocular surface disease, 22
Optical coherence tomography (OCT), 53 Optical correction, 115
Organ culture, 99–101
P
PCR. See Polymerase chain reaction (PCR) Pegaptanib, 82–85
Penetrating keratoplasty, 14, 67, 94, 107 Peripheral iridectomy, 114
Peters’ anomaly, 108
PFGE. See Pulse field gel electrophoresis (PFGE)
Phakic implants, 66 Phakic intraocular lens, 67
Polymerase chain reaction (PCR), 24 Posterior capsulotomy, 114 Posterior polymorphous corneal
dystrophy-1, 38, 59, 108 Povidone–iodine solution, 94 Pre-cutting, 101
Primary open-angle glaucoma, 47 PRK, 59
Pseudomonas aeruginosa, 22, 25, 28, 32 Pulse field gel electrophoresis (PFGE), 9
R
Ranibizumab, 82–85
Refractive surgery, 56, 59–60, 65–66 Reis-Bucklers dystrophy, 58, 59 Resistance, 25–26, 33
Retinitis pigmentosa, 47 Rotational autografts, 118 Runyon classification, 4
S
Schnyder dystrophies, 58, 59
Sclerocornea, 108
Scrapes, 24
Sjogrens syndrome, 21
126 |
Index |
|
|
Slit lamp, 95 |
Transforming growth factor, 37 |
SOD1. See Superoxide dismutase 1 (SOD1) |
Transplantation, 71 |
Specular microscopy, 98, 100 |
Trauma, 22 |
Staphylococcus aureus, 22, 28, 32 |
|
Steroids, 72, 82, 83 |
|
Storage period, 97–99 |
U |
Streptococci, 28 |
Ultrasound biomicroscopy, 111 |
Streptococcus pneumoniae, 22, 24 |
Uveitis, 61 |
Stroma, 55 |
|
Sub-basal nerve plexus, 55 |
|
Superoxide dismutase 1 (SOD1), 43 |
V |
Susceptibility, 25–26 |
VEGF trap, 82–85 |
testing, 24–25 |
Viral keratitis, 56 |
Suture management, 115 |
Visual outcome, 108–109 |
|
VSX1 mutations, 39 |
T |
|
Thiel-Behnke dystrophy, 58 |
Z |
Tigecycline, 30, 33 |
Ziehl Neelsen stain, 6 |
Trachoma, 74 |
|
